Wednesday, October 22, 2014 6:00:17 PM
Not exactly what I said. The effect of therapy will clearly be seen in both the Ph I and II leg. However, should a patient enroll in a checkpoint inhibitor trial (there are many cropping up), after receiving their 6th injection, it will likely skew long term data. Imo it would be to the positive. And I think management will conveniently leave that part out, should this happen: "28/40 still alive after 24 months."
Anyway, things like that happen all the time in clinical trials. There will be a number of patients who don't enroll in further trials, and comparisons can be drawn between them and those that do. It's a good thing. It will result in better therapies down the road. But the thing I'm saying is, should a synergistic effect take place between this DC vaccine and checkpoint inhibitors, as Dr. Black and others opined would occur, then that will only enhance the case for DCVax-Direct.
Um.. with a single injection, 0%. With multiple, 20%. You realize this is absolute speculation on my part of course (let me guess flipper's percentages--single, 48%; multiple, 96% ;D). However, you did say "full solution," which I take to mean only forward progress towards remission. Really, nothing does that today. If Direct can show that it has the ability to increase multiple patient's QoL, PFS, and especially OS, in a clinically meaningful way, then nothing will stop its path to approval. In other words, it doesn't have to even DO very much to become a blockbuster. Keep in mind there are no therapies for these patients. And consider how minor an increase in OS Temodar had in GBM patients (2.6 mo), but how much of a blockbuster it was and is.
No, not really. If Direct gets approval they can conduct one large combination immunotherapy trial and submit its results for label extension. Look up, for instance, how many trials an established pharma like BAX has going on ALL THE TIME... If DCVax gets regulatory approval expect all kinds of trials to crop up.
I'd offer you advice, but I just don't care about your money, unless you give me money to care about your money. I might even be tricking you with the above post...
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM